Helen Dakin joined the Health Economics Research Centre in February 2008. Before starting at HERC, she worked at Abacus International and completed her MSc in Economic Evaluation in Healthcare at City University. She previously graduated from Cambridge University with Masters and Bachelor's degrees in Biochemistry. In 2014, she completed a DPhil at the University of Oxford on the optimal methods for conducting economic evaluations of factorial clinical trials.
Her current projects include: the STAR trial, which evaluates radiotherapy alongside bevacizumab (Avastin) in age-related macular degeneration; the ACHE study, which evaluates clinical tools and thresholds for selecting patients for joint replacement; and the KAT trial, which assesses the cost-effectiveness of different types of knee replacement component.
Research paper on factors influencing NICE decisions available here.
The use of patient-reported outcome measures to guide referral for hip and knee replacement: Part 1 – the development of an evidence based model linking pre-operative score to the probability of gaining benefit from surgery
PRICE A. et al, (2020), Bone and Joint Journal
The use of patient-reported outcome measures to guide referral for hip and knee replacement: Part 2 – a cost-effectiveness analysis
DAKIN H. et al, (2020), Bone and Joint Journal
Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
Reed SD. et al, (2020), Diabetes Care, dc190950 - dc190950
Who gets referred for knee or hip replacement? A theoretical model of the potential impact of evidence-based referral thresholds using data from a retrospective review of clinic records from an English musculoskeletal referral hub
DAKIN H. et al, (2019), BMJ Open
Cooled radiofrequency ablation of the genicular nerves for chronic pain due to osteoarthritis of the knee: a cost-effectiveness analysis based on trial data.
Desai M. et al, (2019), BMC Musculoskelet Disord, 20